Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia A
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hemophilia A
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Only males
Description
This study will follow patients with hemophilia A, who have received a single intravenous administration of SPK-8011 in any prior Spark-sponsored SPK-8011 study. Subjects will be followed for up to a total of 5 years post infusion (including the time on the dosing study).
This study will follow patients with hemophilia A, who have received a single intravenous administration of SPK-8011 in any prior Spark-sponsored SPK-8011 study. Subjects will be followed for up to a total of 5 years post infusion (including the time on the dosing study).
Tracking Information
- NCT #
- NCT03432520
- Collaborators
- Not Provided
- Investigators
- Study Director: Clinical Trial Director Spark Therapeutics, Inc.
Get Well Soon